MAB HUMANIZED (IGG1) ANTI P43489 (TNR4_HUMAN) (ABBV368)

Advanced Solid Tumors Cancer

AbbViemonoclonal_antibodyPhase 1Dormant

CCC

50/ 100

Provisional rating · Methodology v0.2

Rating breakdown

15 Active assets in the Advanced Solid Tumors Cancer cohort.

Asset / Sponsor	Phase	Rating
Budigalimab AbbVie	Phase 1	CCC
Ndi-219216 Nimbus Wadjet, Inc.	Phase 1/2	CC
gfh375 Genfleet Therapeutics (Shanghai) Inc.	Phase 1/2	CC
IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS EGFR (EPIDERMAL GROWTH FACTOR RECEPTOR, RECEPTOR TYROSINE-PROTEIN KINASE ERBB-1, ERBB1, HER1, HER-1, ERBB)), MONOCLONAL ANTIBODY CONJUGATED TO THE PYRROLOBENZODIAZEPINE (PDB) DIMER SGD-1882GAMMA1 HEAVY CHAIN (1-446) (VH (HOMO SAPIENS IGHV4-30-401 (81.4%)-(IGHD)-IGHJ401 (92.9%)) (9.7.9) (1-116)-HOMO SAPIENS IGHG103V, G1M3>G1M17, NG1M1 (CH1 R120>K (213) (117-214), HINGE (215-229), CH2 S3>C (238) (230-339), CH3 E12 (355), M 14 (357) (340-444), CHS (445-446)) (117-446)), (219-214')-DISULFIDE WITH KAPPA LIGHT CHAIN (1'-214') (V-KAPPA (MUS MUSCULUS IGKV14-10001 (86.3%)-IGKJ101 (100%)/HOMO SAPIENS IGKV1-1201 (74.7%)-IGKJ401 (90.9%)) (6.3.9) (1'-107')-HOMO SAPIENS IGKC01 (100%), KM3 A45.1 (153), V101 (191) (108'-214'))DIMER (225-225'':228-228'')-BISDISULFIDECONJUGATED, ON TWO SITE-SPECIFIC DRUG ATTACHMENT ENGINEERED CYSTEINES (C238, C238''), TO PYRROLOBENZODIAZEPINE (PDB) DIMERS SGD-1882, VIA A CATHEPSIN-CLEAVABLE MALEIMIDOCAPROYLVALINE-ALANINE (MC-VAL-ALA) TYPE LINKER AbbVie	Phase 1	CC
ABT-700-VCMMAE AbbVie	Phase 1	CC